Glonway December 11 丨Baiyun Mountain(00874.HK) Announced that according to the actual situation and needs of the current fund-raising investment project, the company has postponed and adjusted the “Danan Pharmaceutical” R&D platform construction project after careful evaluation. The adjusted date for the project to reach the intended useable status is December 31, 2022.
The “Danan Pharmaceutical” R&D platform construction project includes two parts: asset investment and R&D investment. The construction content of the project mainly includes scientific research and development functional zones, innovative drug research and development centers, pharmaceutical research and development centers, laboratory animal research and development centers, and integrated office areas; the research and development direction of the project mainly includes traditional Chinese medicine, chemicals, biological agents, medical devices and in vitro reagent diagnosis, big health products, common technologies and key technologies. The original plan to complete the “Danan Pharmaceutical” R&D platform construction project was completed on December 31, 2019. After research, the completion time for the company's implementation of the “Danan Pharmaceutical” R&D platform construction project has been delayed.
Currently, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. Baiyunshan Pharmaceutical General Factory, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. Baiyunshan Chemical Pharmaceutical Factory, and Guangzhou Baiyunshan Oriental Modern Pharmaceutical Co., Ltd. are currently carrying out more than 40 R&D projects. Relevant research and development work is being actively promoted, and the funds raised will also be disbursed according to the progress of research and development. At the same time, the company is also actively promoting the screening and approval of other newly implemented R&D projects to further accelerate the investment and use of capital raised.
In the future, the company will concentrate more scientific and technological resources for research and development of major projects such as innovative drugs. At the same time, in order to accelerate the completion of fund-raising investment projects, the company may further expand the implementation entities and give full play to the R&D advantages and resources of various subsidiaries/branches.